Sponsors / ALDX
ALDX

Aldeyra Therapeutics, Inc.

Company identity checked against sources

See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.

Follow company
27Trials in this database
10Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
A Safety and Activity Study of NS2 in Subjects With Allergic ConjunctivitisNCT02578914ALDXPhase 2Completed2015-12Actual
SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.NCT03131154ALDXPhase 3Completed2019-04-19Actual
A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye SyndromeNCT03162783ALDXPhase 2Completed2017-07-06Actual
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye DiseaseNCT03404115ALDXPhase 2Completed2018-07-11Actual
ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic ConjunctivitisNCT03494504ALDXPhase 3Completed2018-11-05Actual
The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye DiseaseNCT03879863ALDXPhase 3Completed2019-10-04Actual
A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye DiseaseNCT03916042ALDXPhase 2Completed2019-11-22Actual
The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative VitreoretinopathyNCT04136366ALDXPhase 3Completed2022-06-14Actual
The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.NCT04207736ALDXPhase 3Completed2021-02-16Actual
The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye DiseaseNCT04674358ALDXPhase 2, Phase 3Completed2021-09-12Actual
A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)NCT04728711ALDXPhase 2Completed2022-01-18Actual
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye DiseaseNCT04735393ALDXPhase 3Completed2022-10-11Actual
A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.NCT04847544ALDXPhase 2Completed2021-10-15Actual
A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque PsoriasisNCT04908514ALDXPhase 2Completed2022-01-21Actual
A Clinical Trial to Assess Subjects With Dry Eye Disease.NCT04971031ALDXPhase 2Completed2021-09-08Actual
The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye DiseaseNCT05062330ALDXPhase 3Completed2022-03-04Actual
An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease ChamberNCT05102409ALDXPhase 2Completed2021-10-25Actual
The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic ConjunctivitisNCT05234554ALDXPhase 3Completed2023-04-22Actual
A Study in Subjects With Retinitis PigmentosaNCT05392179ALDXPhase 2Completed2023-06-23Actual
A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic CoughNCT05392192ALDXPhase 2Completed2023-04-13Actual
A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye DiseaseNCT05424549ALDXPhase 2Completed2022-05-09Actual
A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)NCT05717920ALDXPhase 2Completed2023-11-21Actual
A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye DiseaseNCT06389214ALDXPhase 3Completed2024-06-11Actual
A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye DiseaseNCT06424444ALDXPhase 3Completed2024-11-03Actual
A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye DiseaseNCT06493604ALDXPhase 3Completed2025-02-27Actual
A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)NCT06685692ALDXPhase 2Completed2025-06-18Actual
A Clinical Trial Evaluating Patients With Primary Vitreoretinal LymphomaNCT07402876ALDXPhase 3Recruiting2026-12Estimated

Latest recorded trial changes

The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis

NCT05234554 · Aldeyra Therapeutics, Inc.

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Ocular itching evaluated by the Subject.

+ Updated value

measure: Subject-Reported Ocular Itching Score Assessed in the Allergy Chamber

Check registry source · The saved outcome text may be shortened. Check the source for full wording.
A Study in Subjects With Retinitis Pigmentosa

NCT05392179 · Aldeyra Therapeutics, Inc.

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Number of participants with adverse events (AEs)

+ Updated value

measure: Number of Subjects With Serious Adverse Events

Check registry source · The saved outcome text may be shortened. Check the source for full wording.
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

NCT04735393 · Aldeyra Therapeutics, Inc.

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Ocular treatment emergent adverse events (TEAEs)

+ Updated value

measure: Treatment-Emergent Serious Adverse Events (TE-SAEs) of Visual Acuity Decrease; measure: TE-SAEs of Increase in Intraocular Pressure; measure: TE-SAEs of the Cornea; measure: TE-SAEs of the Retina; measure: TE-SAEs of Visual Acuity Decrease; measure: TE-SAEs of Increase in Intraocular Pressure; measure: TE-SAEs of the Cornea; measure: TE-SAEs of the Retina

Check registry source · The saved outcome text may be shortened. Check the source for full wording.